Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605494916 | ||
| 003 | CHVBK | ||
| 005 | 20210128100528.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00261-015-0520-y |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00261-015-0520-y | ||
| 245 | 0 | 0 | |a Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance? |h [Elektronische Daten] |c [Anna Brown, Maria Lindenberg, Sandeep Sankineni, Joanna Shih, Linda Johnson, Suneha Pruthy, Karen Kurdziel, Maria Merino, Bradford Wood, Peter Pinto, Peter Choyke, Baris Turkbey] |
| 520 | 3 | |a Purpose: 18F-FDG PET/CT is used to characterize many malignancies, but is not recommended for localized prostate cancer. This study explores the value of multi-parametric MRI (mpMRI) in characterizing incidental prostate 18F-FDG uptake. Methods: Thirty-one patients who underwent 18F-FDG PET/CT for reasons unrelated to prostate cancer and prostate mpMRI were eligible for this retrospective study. The mpMRI included T2-weighted (T2W), dynamic contrast enhancement (DCE), apparent diffusion coefficient (ADC), and MR spectroscopy (MRS) sequences. Fourteen patients were excluded (n=8 insufficient histopathology, n=6 radical prostatectomy before PET), and final analysis included 17 patients. A nuclear medicine physician, blinded to clinicopathologic findings, identified suspicious areas and maximum standardized uptake values (SUVmax) on 18F-FDG PET/CT. Sector-based imaging findings were correlated with annotated histopathology from whole-mount or MRI/transrectal ultrasound fusion biopsy samples. Positive predictive values (PPVs) were estimated using generalized estimating equations with logit link. Results were evaluated with Kruskal-Wallis and Dunn's multiple comparisons tests. Results: The PPV of 18F-FDG PET alone in detecting prostate cancer was 0.65. Combining 18F-FDG PET as a base parameter with mpMRI (T2W, DCE, ADC, and MRS) increased the PPV to 0.82, 0.83, 0.83, and 0.94, respectively. All benign lesions had SUVmax<6. Malignant lesions had higher SUVmax values that correlated with Gleason scores. There was a significant difference in SUVmax per prostate between the Gleason≥4+5 and benign categories (p=0.03). Conclusions: Focal incidental prostate 18F-FDG uptake has low clinical utility alone, but regions of uptake may harbor high-grade prostate cancer, especially if SUVmax>6. Using mpMRI to further evaluate incidental 18F-FDG uptake aids the diagnosis of prostate cancer. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a 18F-FDG PET |2 nationallicence | |
| 690 | 7 | |a Prostate cancer |2 nationallicence | |
| 690 | 7 | |a Multi-parametric MRI |2 nationallicence | |
| 690 | 7 | |a Incidental FDG uptake |2 nationallicence | |
| 700 | 1 | |a Brown |D Anna |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Lindenberg |D Maria |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Sankineni |D Sandeep |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Shih |D Joanna |u Biometric Research Branch, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Johnson |D Linda |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Pruthy |D Suneha |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Kurdziel |D Karen |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Merino |D Maria |u Laboratory of Pathology, NCI, NIH, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Wood |D Bradford |u Center for Interventional Oncology, NCI, NIH, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Pinto |D Peter |u Urologic Oncology Branch, NCI, NIH, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Choyke |D Peter |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 700 | 1 | |a Turkbey |D Baris |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | |
| 773 | 0 | |t Abdominal Imaging |d Springer US; http://www.springer-ny.com |g 40/8(2015-10-01), 3222-3229 |x 0942-8925 |q 40:8<3222 |1 2015 |2 40 |o 261 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00261-015-0520-y |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00261-015-0520-y |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Brown |D Anna |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lindenberg |D Maria |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sankineni |D Sandeep |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shih |D Joanna |u Biometric Research Branch, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Johnson |D Linda |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Pruthy |D Suneha |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kurdziel |D Karen |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Merino |D Maria |u Laboratory of Pathology, NCI, NIH, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Wood |D Bradford |u Center for Interventional Oncology, NCI, NIH, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Pinto |D Peter |u Urologic Oncology Branch, NCI, NIH, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Choyke |D Peter |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Turkbey |D Baris |u Molecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive, Room B3B85, 20892, Bethesda, MD, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Abdominal Imaging |d Springer US; http://www.springer-ny.com |g 40/8(2015-10-01), 3222-3229 |x 0942-8925 |q 40:8<3222 |1 2015 |2 40 |o 261 | ||